Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asli Özkan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Ageing and Cancer Research & Treatment|January 19, 2026
Immunotherapy: should we worry about immunosenescence?Asli Özkan, Nienke A de Glas, Johanneke E A Portielje
Critical Reviews in Oncology/Hematology|January 10, 2024
Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic reviewAsli Özkan, Frederiek van den Bos, Simon P Mooijaart, et al.
Immunity & Ageing : I & A|November 26, 2024
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapyEstelle Tran Van Hoi, Saskia J Santegoets, Simon P Mooijaart, et al.
International Journal of Cancer|October 4, 2025
Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumorsAsli Özkan, Karlijn de Joode, Ellen Kapiteijn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitorsAsli Özkan, Karlijn de Joode, Ellen Kapiteijn, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Ageing and Cancer Research & Treatment|January 19, 2026
Immunotherapy: should we worry about immunosenescence?Asli Özkan, Nienke A de Glas, Johanneke E A Portielje
Critical Reviews in Oncology/Hematology|January 10, 2024
Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic reviewAsli Özkan, Frederiek van den Bos, Simon P Mooijaart, et al.
Immunity & Ageing : I & A|November 26, 2024
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapyEstelle Tran Van Hoi, Saskia J Santegoets, Simon P Mooijaart, et al.
International Journal of Cancer|October 4, 2025
Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumorsAsli Özkan, Karlijn de Joode, Ellen Kapiteijn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitorsAsli Özkan, Karlijn de Joode, Ellen Kapiteijn, et al.
Pageof 1